Women's Health News

RSS

Oral micronized progesterone effective for women with symptomatic hot flashes

Postmenopausal women who experience bothersome hot flashes or night sweats may have an alternative treatment to estrogen. According to a new study, oral micronized progesterone relieves those symptoms. The results will be presented Saturday at The Endocrine Society's 92nd Annual Meeting in San Diego.

22 Jun 2010

FDA Advisory Committee recommendation against flibanserin will not affect LibiGel program: BioSante

BioSante Pharmaceuticals, Inc. commented today that the recommendation on June 18, 2010 by the FDA Advisory Committee regarding the safety and efficacy of flibanserin (Boehringer-Ingelheim) will have no impact on its own ongoing development program or approval pathway for LibiGel (testosterone gel), for the treatment of hypoactive sexual desire disorder (HSDD).

22 Jun 2010

Women with PCOS may be more vulnerable to BPA exposure: Study

Women with the polycystic ovary syndrome, the most common hormone imbalance in women of reproductive age, may be more vulnerable to exposure to the chemical bisphenol A, found in many plastic household items, according to a new study. The results will be presented Sunday at The Endocrine Society's 92nd Annual Meeting in San Diego.

22 Jun 2010

Women who experience early menopause may have cardiovascular disease later in life: Study

Women who experience early menopause appear to have more than twice the risk of having a heart attack, stroke or other cardiovascular disease event later in life than do women who do not go through early menopause, a new study indicates. The results will be presented Saturday at The Endocrine Society's 92nd Annual Meeting in San Diego.

22 Jun 2010

Ferring announces availability of LYSTEDA for cyclic heavy menstrual bleeding in U.S.

Ferring Pharmaceuticals Inc. announced today the U.S. commercial availability of LYSTEDA™ (tranexamic acid) tablets, the only non-hormonal and non-surgical therapy indicated specifically for the treatment of women with cyclic heavy menstrual bleeding (HMB). In clinical studies, LYSTEDA significantly reduced menstrual blood loss (MBL) over three and six cycles of use with the reduction seen as early as the first cycle of use.

21 Jun 2010

Independent DMC recommends continuation of BioSante's ongoing LibiGel CV and Breast Cancer Safety Study

BioSante Pharmaceuticals, Inc., today announced that the independent Data Monitoring Committee (DMC) of the ongoing LibiGel® Cardiovascular (CV) and Breast Cancer Safety Study unanimously recommended study continuation without modifications, after its third review of the study's unblinded safety data. The review was based on data from almost 1,500 women-years of exposure.

21 Jun 2010

Ostarine increases muscle mass and strength in postmenopausal women: Study

GTx, Inc. announced that Ostarine (GTx-024, formerly MK-2866) increased lean body mass and leg press strength in a head to head study evaluating Ostarine and another selective androgen receptor modulator, MK-3984, in postmenopausal women. The data were presented yesterday at the 2010 Annual Meeting of the Endocrine Society. GTx is developing its lead SARM, Ostarine, for the treatment of cancer induced muscle wasting (cancer cachexia).

21 Jun 2010

Research review calls for new approaches to guard against child abuse

A new international review of research into child welfare services shows that radical changes are needed to improve assessments and support for families where there are concerns about parental abuse.

21 Jun 2010

Study evaluates association between PBDE flame retardants and thyroid function in pregnant women

Pregnant women with higher blood levels of a common flame retardant had altered thyroid hormone levels, a result that could have implications for fetal health, according to a new study led by researchers at the University of California, Berkeley.

21 Jun 2010

Obese women with insulin resistance lose more weight on lower-carbohydrate diet: Study

Obese women with insulin resistance lose more weight after three months on a lower-carbohydrate diet than on a traditional low-fat diet with the same number of calories, according to a new study. The results will be presented Saturday at The Endocrine Society's 92nd Annual Meeting in San Diego.

21 Jun 2010

Too much tea raises the risk of rheumatoid arthritis: Study

Rheumatoid arthritis (RA) a severely debilitating inflammatory disease of the joints is on the rise worldwide. It leads to severe pain, stiffness, swelling and loss of movement of joints like knees, wrist and even fingers. RA affects women more than men. RA occurs in people who develop a rogue immune system that attacks the tissue that lines the joint cavities called the synovium leading to degeneration of the joints and the symptoms of the disease. In 1995 36.4 per 100,000 women were diagnosed with RA whereas in 2005 the number rose to 54 per 100,000 women.

20 Jun 2010

Alcohol consumption guidelines during pregnancy needed: Study

Before 2001 Australian health guidelines recommended that pregnant women should not consume alcohol. These guidelines were introduced in 1992. In 2001 the consensus guidelines recommended avoidance of “high” blood levels of alcohol but did not say no to lower levels of alcohol. In 2009 National Health and Medical Research Council advised that all women planning a pregnancy, pregnant or breastfeeding should not drink alcohol at all.

20 Jun 2010

Researchers review data comparing IUDs and hormonal contraceptives

Women who have had intrauterine devices fitted as contraceptives are less likely to become pregnant than those who have hormone injections, a new review by Cochrane Researchers has found. The review, which focused on women in developing countries, also found a possible link between contraceptive method and disease progression in HIV.

19 Jun 2010

Boehringer Ingelheim disappointed with FDA Advisory Committee recommendations on flibanserin NDA for HSDD

The Reproductive Health Drugs Advisory Committee met today to discuss the new drug application (NDA) for flibanserin 100 mg as a treatment for Hypoactive Sexual Desire Disorder (HSDD) in pre-menopausal women. The advisory committee was convened by and makes recommendations to the U.S. Food and Drug Administration (FDA). The FDA will consider the committee's advice as part of its final assessment of the NDA.

19 Jun 2010

LUHS opens clinic to treat debilitating effects of CPP in women

Loyola University Health System has opened a clinic to treat the debilitating effects of chronic pelvic pain in women. The clinic is located at the Loyola Outpatient Center at 2160 S. First Ave., in Maywood.

19 Jun 2010

Equatorial Guinea strengthens health facilities to boost access to reproductive health services

The Republic of Equatorial Guinea (Republica de Guinea Ecuatorial, along with the United Nations Population Fund (UNFPA), is working to strengthen and equip health facilities throughout the country to boost access to reproductive health services. The rebuilding process includes the construction and renovation of health centers and maternity units as well as proper training for medical students.

19 Jun 2010

Advisory panel recommends FDA approve new "morning after" pill

The New York Times: A Food and Drug Administration advisory panel Thursday recommended that the agency approve "a medicine that could help prevent pregnancy if taken as late as five days after unprotected sex. The pill, called ella, sprang from government labs and appears to be more effective than Plan B, a morning-after pill now available over the counter to women 18 and older that gradually loses efficacy after intercourse and can be taken at latest three days after sex.

18 Jun 2010

Naviscan announces presentations on PEM technology at Society of Nuclear Medicine Annual Meeting

Naviscan's Positron Emission Mammography (PEM) technology was the focus of several presentations and discussions at the Society of Nuclear Medicine Annual Meeting in Salt Lake City. The focus represents a growing interest and validation of how PEM can play an important role in the fight against breast cancer.

18 Jun 2010

FVL gene mutation increases risk of blood clots in breast cancer patients treated with tamoxifen: Study

Women who develop blood clots while taking tamoxifen for early-stage breast cancer are more likely to carry a faulty version of a gene involved in clotting than those who do not develop blood clots, a US study has found.

18 Jun 2010

BioSante announces presentation of LibiGel safety update at ENDO 2010

BioSante Pharmaceuticals, Inc., will present a LibiGel safety update at the 2010 Annual Meeting of the Endocrine Society (ENDO), being held from June 19-22, 2010 in San Diego, California.

18 Jun 2010

Women's Health News

Oral micronized progesterone effective for women with symptomatic hot flashes

FDA Advisory Committee recommendation against flibanserin will not affect LibiGel program: BioSante

Women with PCOS may be more vulnerable to BPA exposure: Study

Women who experience early menopause may have cardiovascular disease later in life: Study

Ferring announces availability of LYSTEDA for cyclic heavy menstrual bleeding in U.S.

Independent DMC recommends continuation of BioSante's ongoing LibiGel CV and Breast Cancer Safety Study

Ostarine increases muscle mass and strength in postmenopausal women: Study

Research review calls for new approaches to guard against child abuse

Study evaluates association between PBDE flame retardants and thyroid function in pregnant women

Obese women with insulin resistance lose more weight on lower-carbohydrate diet: Study

Too much tea raises the risk of rheumatoid arthritis: Study

Alcohol consumption guidelines during pregnancy needed: Study

Researchers review data comparing IUDs and hormonal contraceptives

Boehringer Ingelheim disappointed with FDA Advisory Committee recommendations on flibanserin NDA for HSDD

LUHS opens clinic to treat debilitating effects of CPP in women

Equatorial Guinea strengthens health facilities to boost access to reproductive health services

Advisory panel recommends FDA approve new "morning after" pill

Naviscan announces presentations on PEM technology at Society of Nuclear Medicine Annual Meeting

FVL gene mutation increases risk of blood clots in breast cancer patients treated with tamoxifen: Study

BioSante announces presentation of LibiGel safety update at ENDO 2010

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News